The count is set at the consultation, usually one to three. Change is described as appearing over one to three months, but the plan varies greatly with the purpose and the processing scope, so there is no standard count. The cost is high, so many people have one session and decide after seeing the response.

Placing cells in the skin targets regeneration in that area; intravenous delivery targets whole-body condition. The goals differ, so one cannot cover the other, which is why they are combined. Doing both at once cuts down on visits, but the cost and time of a single session go up accordingly.

Minimal manipulation is permitted at medical institutions. Cells expanded through culture are classified as a drug requiring separate approval, and administering them without it is illegal. It is essential to confirm the scope of processing before the treatment. If a clinic cannot say clearly which scope it works within, that is reason to reconsider.